Technology Sharing Sample Clauses
The Technology Sharing clause establishes the terms under which parties agree to share technological resources, such as software, patents, or proprietary know-how, during the course of their collaboration. Typically, this clause outlines what specific technologies are included, the permitted uses by each party, and any restrictions or obligations regarding confidentiality and intellectual property rights. Its core function is to facilitate cooperation and innovation between parties while protecting each party’s proprietary interests and ensuring that shared technology is used appropriately.
POPULAR SAMPLE Copied 1 times
Technology Sharing. (a) Clearside shall provide to Arctic Vision electronic copies of the documents relating to Licensed Products set forth on Exhibit B(i) hereto within [***] of Clearside’s procurement or generation of such documents.
(b) Clearside shall provide to Arctic Vision electronic copies of each of the documents set forth on Exhibit B(ii) hereto within [***] of Clearside’s procurement or generation of such documents.
(c) To the extent not included in Exhibit B(ii), Clearside shall also provide to Arctic Vision all additional data and documents Controlled by the Clearside Entities and relating to Licensed Products that are [***] for Arctic Vision to file IND(s) in the Territory, including Know-How, regulatory data, clinical data, [***] which Arctic Vision did not and could not reasonably Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. know of. Notwithstanding the foregoing, to the extent any data and documents are required by a Regulatory Authority in connection with Arctic Vision’s filing of IND(s) or Drug Approval Application(s) in the Territory, Clearside shall (i) provide to Arctic Vision all such data and documents Controlled by the Clearside Entities [***] existing as of the Effective Date for the Licensed Products, and (ii) use Commercially Reasonable Efforts to provide to Arctic Vision all such data and documents Controlled by (A) [***] and (B) [***].
(d) Throughout the Term, Clearside shall provide Arctic Vision with an update of any material regulatory developments (e.g., NDA filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by Clearside, Clearside’s Affiliates or licensees, and upon Arctic Vision’s request, Clearside shall make available to Arctic Vision copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case that are related to Licensed Product in the Field and Controlled by the Clearside Entities or any of their sublicensees (collectively, the “Clearside Product Data”), to the extent (i) such Clearside Product Data are [***] for any Arctic Vision Entity or their sublicensees to Develop, Manufacture or have Manufactured, or Commercialize Licensed Product in the Field in the Territory in accordance with this Agreement and are Controlled by the Clearside Entities, (ii) such Clearside Product Data ar...
Technology Sharing. Each of AL2, ReSound and Danavox will make available to the other parties the use of its respective Technology to perform its portions of the Development Program, will provide to the other parties, as soon as reasonably available, copies of the tangible aspects of such Technology including, without limitation, layout design vellums, specifications and other engineering documents, and, subject to the terms and conditions of this Agreement, will supply the personnel, facilities, and materials necessary to carry out its respective portion of the Development Program and to allow the manufacture, use and selling of the Products pursuant to the licenses granted under this Agreement. In particular, AL2 shall be responsible for providing the AL2 Technology, Danavox shall be responsible for providing the Danavox Technology and ReSound shall be responsible for providing the ReSound Technology.
Technology Sharing. Upon the Galderma Start Date, and thereafter at least [***] or more frequently upon Galderma’s request, Sol-Gel shall provide to Galderma all data and documents Controlled by any Sol-Gel Entities and related to the Licensed Product that are reasonably necessary or useful for Galderma to Commercialize and perform Medical Affairs with respect to Licensed Product in the Territory or to perform its obligations under Section 4.02 (Galderma Regulatory Responsibility), including Licensed Know-How, regulatory data, and clinical data. Throughout the Term, Sol-Gel shall provide Galderma with updates of any material regulatory developments (e.g., NDA or NDS filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by Sol-Gel, or Sol-Gel’s Affiliates or licensees. In addition, at least [***] or more frequently upon Galderma’s request, Sol-Gel shall make available to Galderma copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case, that are related to Licensed Product in the Field and Controlled by the Sol-Gel Entities or any of their licensees or sublicensees (collectively, the “Sol-Gel Product Data”), to the extent (i) such Sol-Gel Product Data are necessary or reasonably useful for any Galderma Entity to Commercialize or perform Medical Affairs with respect to Licensed Product in the Field in the Territory in accordance with this Agreement, or (ii) such Sol-Gel Product Data are required by Regulatory Authority in the Territory in connection with the Commercialization of or performance of Medical Affairs with respect to Licensed Product in the Field in the Territory.
Technology Sharing. Sovello will agree to share certain technology advancements (namely: [****]) as implemented in production by the closing date of this agreement. Evergreen will acquire full rights to make, use, have made, sublicense, etc., these technology advancements without royalty payments in perpetuity. Once Sovello has provided the above listed technology advancements, Evergreen will acknowledge the completion of this Technology Sharing in writing. Draft Term Sheet String Ribbon License Agreement Evergreen — Exhibit A We agree to this non-binding overview of principals as basis for a new license agreement between Evergreen and Sovello replacing the existing QLA and LTTA unless otherwise stated. Thalheim, 18-3-2010 Marlboro, March 3, 2010 /s/ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ Sovello AG Evergreen Solar Inc. Loan Agreement dated April 30, 2007 incl. amendments dated May 22, 2007 and September 1, 2008 Tranche A 37.500.000,00 -10.220.261,31 27.279.738,69 69.836,13 Tranche B **) 5.786.306,29 -3.841.436,42 1.944.869,87 4.978,87 ▇▇▇▇▇▇▇ ▇ ▇,▇▇ ▇,▇▇ ▇,▇▇ ▇▇▇▇▇▇▇ ▇ 25.000.000,00 -6.813.507,54 18.186.492,46 46.557,42 Interest rate swap ***) 318.209,10 Total 68.286.306,29 -20.875.205,27 47.411.101,02 439.581,52 *) According to bank confirmation Shareholders’ payments were used for loan redemptions (EUR 20.875.205,27) and interest payments (EUR 509.696,76). **) Regarding Tranche B Q-Cells SE and REC ASA have made a payment as security for Evergreen (EUR 1.942.451,02). Therefore, Tranche B was not yet formally reduced. ***) The interest rate swap is a fixed-for-floating rate swap and refers to Tranche A. The swap was terminated by the Syndicated Banks together with the Loan Agreement in January 2010. ****) Interest incurred until closing date must be calculated at closing. TOTAL Sales Revenue K EUR 219.297 111.731 10.293 12.342 20.750 19.584 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] TOTAL COGS K EUR 167.242 127.318 10.789 14.545 19.838 18.694 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] GROSS PROFIT K EUR 52.054 -15.588 -496 -2.203 912 890 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Gross Margin % 23,7 % -14,0 % -4.8 % -17.8 % 4.4 % 4.5 % [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [*...
Technology Sharing. 6.1 Notwithstanding the use of the term ‘Technology Sharing’ and notwithstanding anything contained in this Agreement or any of the Related Agreements to the contrary, nothing in any of the Transaction Documents is intended to or is to be interpreted as an obligation of Kamada to transfer legal title to any of the intellectual property assets licensed by Kamada under this Agreement to ▇▇▇▇▇▇. Further, for the avoidance of doubt, the term ‘Technology Sharing Plan’ (and its related defined terms) is intended to refer to the process by which Kamada will disclose to ▇▇▇▇▇▇ and will train ▇▇▇▇▇▇ with respect to the skills, knowledge, technologies and methods of manufacturing that Kamada possesses (or will develop during the Term) to ensure that ▇▇▇▇▇▇ is able to exploit such skills, knowledge, technologies and methods in the ▇▇▇▇▇▇ Territory as more specifically detailed in Exhibit 1.67 to this Agreement.
6.2 Kamada expressly undertakes, under the provisions set forth below and as further set forth in the Technology Sharing Plan (Exhibit 1.67) the following:
(a) by [*****], for no additional consideration, to complete a speedy and efficient disclosure to ▇▇▇▇▇▇ of all Technology Sharing Documentation, including, without limitation, Regulatory Documentation, all documentation related to yield improvement for A1PI, and all other information, materials and documentation reasonably necessary for or directly related to ▇▇▇▇▇▇’▇ exercise of the rights licensed herein as listed in Exhibit 1.39, as well as all copies of documents reasonably requested by ▇▇▇▇▇▇, provided that such documents are in Kamada’s possession and that such access shall comply with all state and federal statute requirements;
(b) until the end of the Technology Sharing Term, to provide ▇▇▇▇▇▇ and relevant health authorities with such access to Kamada’s offices and laboratory and production facilities in Israel as is reasonable to advance the sharing of Kamada’s technology under the Technology Sharing Plan, upon prior coordination with Kamada of at least [*****] and during normal business hours, provided that such visits may not unduly burden Kamada’s normal work activities, and to provide consultation and advice reasonably requested by ▇▇▇▇▇▇ or any said authority during any such visit, all for no additional consideration;
(c) for [*****], to provide ▇▇▇▇▇▇ and ▇▇▇▇▇▇’▇ third party contract partners with all other consultation and advice necessary or evidently beneficial for effecting said discl...
Technology Sharing. (a) Verona shall provide to Nuance electronic copies of the documents relating to Licensed Products set forth on Exhibit B hereto promptly after the Effective Date but in any event within ninety (90) days of the Effective Date.
(b) To the extent not included in Exhibit B, Verona shall also provide to Nuance all Verona Know-How, and all other additional data and documents existing as of the Effective Date that are Controlled by the Verona Entity and reasonably necessary for the Nuance Entity to Develop or Commercialize Licensed Product in the Field in the Territory in accordance with this Agreement, which Nuance did not and could not reasonably know of.
(c) Throughout the Term, Verona shall provide Nuance with an update of any material regulatory developments (e.g., NDA filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by the Verona Entity, and upon Nuance’s request, Verona shall make available to Nuance copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case that are related to Licensed Product in the Field and Controlled by the Verona Entity (collectively, the “Verona Product Data”), to the extent such Verona Product Data is reasonably necessary for any Nuance Entity to Develop or Commercialize Licensed Product in the Field in the Territory in accordance with this Agreement.
(d) No provision of this Agreement shall require Verona to provide to Nuance any intellectual property or information (including Know-How, data, documents or files) licensed to, or provided to, Verona by Ligand UK Development Limited (formerly Vernalis Development Limited).
(e) Throughout the Term, Verona shall provide reasonable technical assistance as reasonably requested by Nuance in support of the Development and Commercialization of the Licensed Product in the Field in the Territory, at Nuance’s costs and expenses.
Technology Sharing. Cooperate as required in making its ------------------ technology available to the TeleCor division and assisting in the conversion of the Heartline system described below.
Technology Sharing. Monsanto agrees that it will provide access to its pelargonic acid technology and the Agent agrees that it will provide access its ammonium nonanoate technology, including, but not limited to, access to formulations, know-how and registrations for use within GroundClear and Roundup branded products. If the Agent does not deliver a Convenience Termination Notice on January 15, 2021, the parties will enter into a broader technology sharing agreement on terms to be mutually agreed by the parties.
Technology Sharing. The parties agree to disclose to the other during the term of this Agreement their respective technologies and capabilities, including but not limited to E-Cruiter's Helius Platform, in the context of joint exploration of licensing and cross-licensing opportunities of such technologies and capabilities on mutually beneficial terms.
Technology Sharing. (a) Sol-Gel shall provide to SLP all data and documents Controlled by the Sol-Gel Entities and related to the Licensed Product that are reasonably necessary for SLP to Commercialize Licensed Product in the Territory, including Licensed Know-How, regulatory data, and clinical data. Throughout the Term, Sol-Gel shall provide SLP with an update of any material regulatory developments (e.g., NDA or NDS filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by Sol-Gel, or Sol-Gel’s Affiliates or licensees, and upon SLP’s request, Sol-Gel shall make available to SLP copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case that are related to Licensed Product in the Field and Controlled by the Sol-Gel Entities or any of their licensees (collectively, the “Sol-Gel Product Data”), to the extent (i) such Sol-Gel Product Data are reasonably necessary for any SLP Entity to Commercialize the Licensed Product in the Field in the Territory in accordance with this Agreement and are Controlled by the Sol-Gel Entities,